Tools chosen: kalshi_direct claude_news gdelt_news kalshi_related polymarket_related

Sub-questions (Fermi decomposition)

Planner reasoning

This is a policy-action question hinging on whether Trump takes executive action eliminating IVF cost for at least one cycle before Jan 2029. The key is tracking executive orders, federal rule-making, and stated intentions. Market price is the primary anchor; news and related markets provide signal.

# Current state The resolution criterion requires an action that **eliminates the cost of at least one IVF cycle** before Jan 20, 2029. Currently, the administration has taken incremental steps (drug discounts, voluntary employer guidance) but has not eliminated any IVF costs for any patient population. # Timeline of key events - **2025-02 (exact date unconfirmed)** — Trump signs EO directing policy recommendations on IVF access/cost reduction; no cost elimination mandated [AJMC, Prelude Fertility — confirmed] - **2025-05** — 90-day deadline for EO recommendations passes with no published findings [NBC News — confirmed] - **2025-10-16** — Trump announces EMD Serono agreement: 84% discount on specific IVF drug protocols via TrumpRx.gov [Prelude Fertility — confirmed] - **2025-10-16** — New federal guidance allows employers to offer fertility benefits separately (voluntary, not mandatory) [Prelude Fertility — confirmed] - **2026-05-11** — Trump admin proposes new voluntary IVF benefit expansion through employers [Benzinga — confirmed] - **2026-05-12** — Trump calls himself "Father of Fertility"; fumbles reporter question on IVF plan [GDELT — confirmed] - **2026-05-21** — CNN: "IVF treatment costs were supposed to drop under Trump. That's still a long way off." [CNN — confirmed] - **2026-06-10** — Trump admin moves to protect frozen embryos from destruction (complicates IVF expansion) [Daily Signal — confirmed] - **2026-06** — Texas GOP anti-IVF platform creates Republican split; Paxton distances himself [Texas Tribune — confirmed] --- # Event Will Trump take action eliminating the cost of at least one IVF cycle before January 20, 2029? # Outcomes to forecast - **Yes** — President takes action eliminating cost of ≥1 IVF cycle before Jan 20, 2029 - **No** — No such action taken # Kalshi market anchor **KXFREEIVF-29 current YES price: 14%** (as of data pull) - 7-day change: −2%; 30-day change: flat - Range over 59 days: 10%–17%; avg daily volume: 53 contracts - Trend: slight downward drift; low liquidity # Sub-question answers 1. **Has Trump signed any EO on IVF, and what did it actually mandate?** — Yes, signed ~Feb 2025. It directed policy *recommendations* to reduce costs; it did **not** mandate cost elimination or create new rights/guarantees. [AJMC, Prelude Fertility] 2. **Status of Feb 2025 EO and follow-up recommendations?** — 90-day deadline passed May 2025 with no published findings. October 2025 follow-up = 84% drug discount via TrumpRx.gov (voluntary, partial) and employer guidance (voluntary). As of May 2026, full cost elimination remains distant. [NBC News, KFF, CNN] 3. **Does the President have legal authority to eliminate IVF costs unilaterally?** — No clear unilateral path. Congressional legislation would be required for universal coverage/mandates. 2024 Senate bills failed; 2025 House bill (Underwood) has no movement. [KFF] 4. **Concrete steps toward free IVF announced?** — Only: (a) 84% EMD Serono drug discount (covers drugs only, not procedures); (b) voluntary employer benefit framework. Neither eliminates a full cycle cost. Medicaid still doesn't cover IVF in most states. [KFF, Prelude Fertility] 5. **Historical base rate of campaign healthcare promises fully implemented?** — Research silent on specific base rate, but analogous promises (e.g., drug pricing, ACA repeal/replace) routinely fail or deliver partial implementation. Context suggests low base rate (~10–25%). # Key facts (high-confidence, factual) 1. [KFF] Drug discount covers only IVF medications; remaining procedural costs (~$10,000–$15,000/cycle) are unaddressed 2. [KFF] Medicaid covers IVF in essentially no states; TrumpRx benefit inaccessible to most Medicaid enrollees 3. [KFF] Universal IVF coverage requires Congressional action; no viable bill exists 4. [Prelude Fertility] Employer IVF benefit framework is voluntary — no mandated coverage 5. [Daily Signal] June 2026 embryo protection moves could complicate IVF expansion (political cross-pressure from pro-life groups) 6. [NBC News] Catholic Medical Association and USCCB have lobbied administration *against* IVF promotion # Cross-market signals - **Kalshi related:** No directly comparable markets. "Trump bring back manufacturing" (17%) and "government cuts ≥$250B" (10%) suggest market skepticism on ambitious Trump domestic policy delivery - **Polymarket:** No active IVF markets found - **Sportsbook:** N/A # Analyst opinions and speculation - [KFF] Assessment: October 2025 actions are incremental; universal free IVF requires legislation that has zero current momentum - [CNN, May 2026] Explicitly frames cost reduction as "still a long way off" — over 1 year into term - Political cross-pressure: pro-life religious groups actively opposing; Texas GOP anti-IVF platform signals intraparty friction # Directional lean per outcome - **Yes (14%):** Trump has political incentive (pronatalist branding, "Father of Fertility"); some incremental action exists; ~2.5 years remain in term - **No (86%):** EO was study-only; no congressional path; voluntary employer framework ≠ cost elimination; pro-life pressure cuts against; CNN May 2026 confirms stall; resolution bar ("eliminates cost") is very high # Gaps / unknowns - Whether any HHS rulemaking could mandate insurer coverage without Congress (legal ambiguity) - Whether a future deal with more drug/procedure companies could cumulatively meet resolution threshold - Definition of "eliminates cost" — would a 100% subsidy for one specific population (e.g., veterans) qualify? # Calibration anchors - **Kalshi YES price: 14%** — primary anchor; has been stable (flat 30-day) - ACA repeal (full campaign promise): never passed despite majority - Drug pricing EOs: signed but largely blocked/reversed - Given ~2.5 years remaining, incremental drift possible but full cost elimination highly unlikely without Congress

1. Forecast 1 is a pure fallback uniform distribution (50/50) with no substantive rationale, making it diagnostically useless and wildly miscalibrated given the strong directional evidence — it should be disregarded entirely as it ignores the Kalshi anchor, legislative barriers, and all factual evidence in the brief. 2. Forecast 2 slightly under-weights the Kalshi anchor at 14% by moving to 12%, but the brief explicitly flags a key ambiguity neither forecaster adequately addressed: whether a 100% subsidy for a narrow population (e.g., veterans or active military) could satisfy the resolution criterion, which could be achieved via executive action through VA/DoD without Congress. 3. Neither forecaster explicitly grappled with the embryo protection move from June 2026, which signals active pro-life cross-pressure that makes Trump *less* likely to expand IVF access going forward — this is a new negative signal that should push Yes probabilities marginally lower than the current 14% Kalshi price. 4. Both forecasters under-weighted the HHS rulemaking ambiguity noted in the brief — if an insurer coverage mandate is legally achievable via executive rulemaking, that would represent a meaningful non-zero path to Yes that is distinct from the congressional route, and neither forecaster assigned it separate probability weight. 5. The historical base rate sub-question (analogous promises like ACA repeal and drug pricing EOs failing or delivering only partial implementation) points to roughly 10–25% success, and the brief notes drug pricing EOs were "largely blocked/reversed" — Forecast 2's 12% sits at the lower bound of this range, which may be slightly too pessimistic given ~2.5 years remain and pronatalist branding remains politically salient for Trump.

12% (38% confidence)

Yes: 12% No: 88%

Forecast 1's uniform 50/50 is a non-substantive fallback and disregarded. Forecast 2's 12% aligns with the Kalshi 14% anchor and the strong evidence: the EO only requested recommendations, all concrete actions are voluntary/partial (drug discounts, employer guidance), universal coverage requires Congress with no viable bill, and pro-life cross-pressure works against expansion. A narrow-population subsidy (veterans) is a residual Yes path keeping probability meaningfully above zero, but the high resolution bar and ~2.5 years remaining justify staying near the market price.

Total pipeline time: 99.9s